{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:30:40Z","timestamp":1764221440303,"version":"3.46.0"},"reference-count":35,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Medical Center-University of Freiburg, Germany"},{"name":"the Faculty of Medicine of the University of Freiburg"},{"name":"the Else Kr\u00f6ner-Fresenius Foundation","award":["2016_A133"],"award-info":[{"award-number":["2016_A133"]}]},{"DOI":"10.13039\/501100014178","name":"Riemser Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014178","id-type":"DOI","asserted-by":"crossref"}]},{"name":"internal resources of the Medical Center-University of Freiburg"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Short induction followed by high-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT) is effective in newly diagnosed elderly patients with primary central nervous system lymphoma (PCNSL) but associated with significant toxicity. Geriatric assessments (GAs) may help to predict treatment risk and prognosis, yet no standardized GAs exist for PCNSL. Our aim was to evaluate the impact of GA on HCT-ASCT eligibility and survival. Methods: We analyzed 65 patients &gt; 65 years treated in the MARiTA and MARTA studies. Treatment comprised 2 cycles of rituximab, HD-MTX and cytarabine followed by HCT-ASCT. GAs at diagnosis were analyzed for progression-free survival (PFS), overall survival (OS) and premature end of treatment (pEOT). Results: After median follow-up of 43 months, 12-month PFS\/OS were 69.2% (95% CI 56.5\u201378.9%)\/70.8% (58.1\u201380.2%) from diagnosis and 80.4% (66.6\u201388.9%)\/84.3% (71.1\u201391.8%) from time of HCT-ASCT. ECOG PS \u2265 2, Lachs geriatric screening (Lachs) \u226530% and Cumulative Illness Rating Scale-Geriatric (CIRS-G) \u22656, \u22657 and \u22658, respectively, were significantly associated with pEOT in univariate analysis (UVA). In multivariate analysis (MVA), CIRS-G remained significant. A composite EBL score (ECOG PS \u2265 2, Barthel Index of Activities of Daily Living (Barthel) &lt; 20, Lachs \u2265 30%) \u22641 predicted successful completion of HCT-ASCT in &gt;90% of patients. ECOG PS \u2265 2 and Barthel &lt; 20 were associated with decreased PFS and OS in UVA; ECOG PS \u2265 2 remained significant in MVA. Conclusions: This is the first study to link GA with treatment feasibility in elderly PCNSL patients undergoing intensive therapy. Our results will be validated in the PRIMA-CNS trial (EudraCT 2020-001181-10).<\/jats:p>","DOI":"10.3390\/cancers17233759","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T10:46:18Z","timestamp":1764067578000},"page":"3759","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Geriatric Assessment Scores as Predictors of Intensive Therapy Feasibility and Survival in Elderly Patients with Primary CNS Lymphoma"],"prefix":"10.3390","volume":"17","author":[{"given":"Lisa K.","family":"Isbell","sequence":"first","affiliation":[{"name":"Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Vreden","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-1589","authenticated-orcid":false,"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roswitha","family":"Uibeleisen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, 70174 Stuttgart, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Friedl","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Geriatrics, Klinikum Stuttgart, Prie\u00dfnitzweg 24, 70374 Bad Cannstatt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Neumaier","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, 70174 Stuttgart, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0088-1915","authenticated-orcid":false,"given":"Julia","family":"Wendler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, 70174 Stuttgart, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andras","family":"Orban","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza M.","family":"Lauer","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Fricker","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Malenica","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Illerhaus","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, 70174 Stuttgart, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-2125","authenticated-orcid":false,"given":"Elisabeth","family":"Schorb","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e318266fcb2","article-title":"Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial","volume":"79","author":"Roth","year":"2012","journal-title":"Neurology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ajh.23812","article-title":"A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial","volume":"89","author":"Olivier","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2023.11.010","article-title":"Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Ferreri","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","article-title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: Results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Liu, J., Guo, J., Sun, X., Liu, Y., and Gao, C. (2021). Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.799721"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1517\/14656561003767456","article-title":"Treatment approaches for primary CNS lymphomas","volume":"11","author":"Carrabba","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","article-title":"First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)\u2014A systematic review and individual patient data meta-analysis","volume":"26","author":"Kasenda","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","author":"Villano","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000495284","article-title":"Primary CNS Lymphoma in the Elderly: The Challenge","volume":"141","author":"Siegal","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3892\/ijo.2021.5180","article-title":"Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review)","volume":"58","author":"Liu","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: An LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00277-023-05140-6","article-title":"Long term outcomes in older patients with primary central nervous system lymphoma: An analysis of the Texas Cancer Registry","volume":"102","author":"Burns","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2020002064","article-title":"High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: A pilot study","volume":"4","author":"Schorb","year":"2020","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(23)00371-X","article-title":"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): A single-arm, phase 2 trial","volume":"11","author":"Schorb","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_16","first-page":"1191.e1","article-title":"Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transpl. Cell. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16592","article-title":"Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: Methotrexate dose intensity correlates with response and survival","volume":"190","author":"Poynton","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bmt.2017.101","article-title":"High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: A multi-centre retrospective analysis from the United Kingdom","volume":"52","author":"Kassam","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: A systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JOP.18.00180","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary","volume":"14","author":"Mohile","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bjh.17799","article-title":"Advances in treatment of elderly primary central nervous system lymphoma","volume":"196","author":"Isbell","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/bmt.2010.188","article-title":"Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"46","author":"Plattel","year":"2011","journal-title":"Bone Marrow Transpl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified Geriatric Assessment in Older Patients with Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12288-022-01567-5","article-title":"Charlson Comorbidity Index (CCI) in Diffuse Large B-cell Lymphoma: A New Approach in a Multicenter Study","volume":"39","author":"Eren","year":"2023","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Isbell, L.K., Uibeleisen, R., Friedl, A., Burger, E., Dopatka, T., Scherer, F., Orban, A., Lauer, E., Malenica, N., and Semenova, I. (2023). Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients\u2014The randomized phase III PRIMA-CNS trial. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11193-7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s00277-018-3468-5","article-title":"Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma","volume":"97","author":"Farhi","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ajh.26919","article-title":"Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers","volume":"98","author":"David","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e071350","DOI":"10.1136\/bmjopen-2022-071350","article-title":"Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: Study protocol for a phase II, multicentre, non-randomised study","volume":"13","author":"Yamasaki","year":"2023","journal-title":"BMJ Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-112-9-699","article-title":"A simple procedure for general screening for functional disability in elderly patients","volume":"112","author":"Lachs","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/09638288809164103","article-title":"The Barthel ADL Index: A reliability study","volume":"10","author":"Collin","year":"1988","journal-title":"Int. Disabil. Stud."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s15006-023-2809-z","article-title":"Screening according to Lachs as common thread in geriatric assessment","volume":"165","author":"Krupp","year":"2023","journal-title":"MMW Fortschr. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","article-title":"The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model","volume":"27","author":"Gordon","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3759\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:27:18Z","timestamp":1764221238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":35,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17233759"],"URL":"https:\/\/doi.org\/10.3390\/cancers17233759","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}